Scotland has become the world's first country to introduce a simple blood test for Type 1 diabetes patients, enabling them to stop taking insulin by improving the accuracy of diagnosis.
The routine C-peptide test, introduced today (November 1), will allow doctors to know how much insulin someone with diabetes is making themselves.
The roll-out of test follows a two-year pilot study in NHS Lothian led by diabetes and endocrinology consultant Professor Mark Strachan.
Strachan said: "C-peptide helps diabetes specialists make a more accurate diagnosis of the cause of diabetes, and that means we can get people on the most appropriate treatment. In some instances, C-peptide testing allowed people to stop very long-standing insulin therapy; this can be life-transforming."
Pharmacists and pharmacy technicians are set to receive up to £15.9 million over the next four years which will help them thrive in multidisciplinary healthcare teams and enable expansion of frontline staff in primary and community care.
The funding, which is part of the Pharmacy Integration Programme allocation, will improve registered pharmacy professionals' skills, through a range of training
and development opportunities.
The programme is a part of education reform for pharmacy professionals and will allow them to identify career pathways.
Health Education England and NHS England will work in partnership to develop "a formal portfolio recognition process to identify the existing skills, training and experience gained by pharmacists working in primary care, allowing them to work more flexibly and better support GP services", HEE said in a statement today (November 8).
A further 18 new products have been entered the list of 'Drugs for which Discount is Not Deducted' (DND) in Part II of the Drug Tariff on 1 November, following applications made by the PSNC.
This takes the number of products added to the DND list by the Department of Health and Social Care (DHSC) and the NHS Business Services Authority (NHSBSA) in the
last 18 months to over 400.
The latest list of products include Aciclovir 200mg/5ml oral suspension sugar free, Acitretin 25mg capsules and Strattera 4mg/1ml oral solution.
The DND list is updated monthly by the DHSC and includes grouped and individual items, the latter being separately listed in Part II of the Drug Tariff. Any items covered by the 'Group Items' heading are not listed again individually in Part II.
See here to see a list of all the monthly changes to the DND status of products.
Britain will start to roll out Merck's molnupiravir Covid-19 antiviral pill through a drug trial later this month, Susan Hopkins, chief medical adviser at the UK Health Security Agency said on Sunday (November 7).
Last week Britain became the first country in the world to approve the potentially game-changing Covid-19 antiviral pill, jointly developed by US-based Merck & Co Inc and Ridgeback Biotherapeutics.
The government said in October it had secured 480,000 courses of the Merck drug, as well as 250,000 courses of an antiviral pill developed by Pfizer Inc.
Asked about the molnupiravir approval, Hopkins told BBC television: "That is great news and it will start to be rolled out through a drug trial in the end of this month/the beginning of December."
Hopkins said all the trials so far had been done with the unvaccinated, so this would help understand how it will work in the wider vaccinated population.
US pharmaceutical giant Johnson & Johnson on Friday (November 12) announced plans to break up into two listed companies, separating its consumer health arm that sells Band-Aids and Tylenol from its pharmaceutical division.
Johnson & Johnson said in a statement it will create "two global leaders that are better positioned to deliver improved health outcomes for patients and consumers through innovation."
It plans to complete the separation in 18-24 months, creating two publicly traded companies. CEO Alex Gorsky said the decision was made following a "comprehensive
review."
The board and management believe the split is "the best way to accelerate our efforts to serve patients, consumers, and healthcare professionals, create opportunities
for our talented global team, drive profitable growth, and -- most importantly -improve healthcare outcomes for people around the world," he said.
As the government today (November 15) announced plans to expand Britain's booster programme for Covid-19 vaccinations to cover all adults aged over 40, NHS Confederation welcomed the move.
The announcement follows the Joint Committee on Vaccination and Immunisation (JCVI) statement that all healthy adults aged 40-49 should be offered a booster, six
months after their second dose, and that 16 and 17 year olds should be invited to have a second dose.
Accepting the JCVI's advice, health and social care secretary Sajid Javid said: "All 4 parts of the UK intend to follow the JCVI's advice.
"We know immunity to Covid-19 begins to wane after 6 months and new data published today shows a third dose boosts protection against symptomatic infection to more than 90% - this highlights just how important it is that everyone eligible gets their top-up jabs as soon as possible."
Considering the shortage of Fluoxetine 10mg tablets, the Department of Health and Social Care (DHSC) has extended the serious shortage protocol (SSP) for the medicine to February 11, 2022.
Earlier the SSP for Fluoxetine 10mg tablets was set to expire on November 12.
Extension of the transition period will enable use of No Cheaper Stock Obtainable (NCSO) endorsement and use of EPS tokens to claim for supplies made in accordance
with SSPs.
The NHS Business Services Authority (NHSBSA) has accepted that either the new 'SSP' or existing 'NCSO' endorsement for any SSP claims can be submitted using electronic prescriptions (EPS) tokens of FP10 paper prescriptions, during the period.
The General Pharmaceutical Council (GPhC) has launched a consultation on whether people agree or disagree that its hearings should continue to be held remotely when it is fair and practical to do so.
The 12-week consultation - which ends on February 8 - seeks views on a proposed permanent change to the GPhC's procedural rules which will allow it to conduct
hearings and meetings by teleconference or videolink.
The pharmacy regulator is seeking changes to enable it to continue to hold some hearings remotely in the future following positive feedback from those taking part
in hearings during the Covid-19 pandemic which the GPhC held remotely by videolink.
"In cases where the GPhC investigates a concern about a pharmacist or pharmacy technician and decides there is evidence to show that their fitness to practise may
be impaired, the case may need to be referred for a hearing before a committee," GPhC said in a statement today (November 16).
The Royal Pharmaceutical Society is set to cease all its remaining financial investments in fossil fuels latest by the end of 2022.
The decision taken today (November 17) at the RPS Assemble, is part of the organisation's "continued drive to become an environmentally responsible organisation."
Calling it a significant move, RPS president Claire Anderson said: "RPS will divest from fossil fuels as soon as possible.
"RPS will instruct its investment managers immediately to ensure that we will be completely disinvested by the end of 2022 and hopefully sooner."
Environment and human wellbeing have always been a core consideration of RPS investment, however it was not enough to offset the negative impacts of climate change, the organisation said.
The government announced today (November 19) that it would add booster shots to the Covid-19 pass for outbound international travel, though it added they would not be added to the domestic pass at this time.
The Department of Health and Social Care said travellers who have had a booster or a third dose would be able to demonstrate their vaccine status through the NHS Covid Pass from today.
The addition will enable those who have had their booster or third dose to travel to countries including Israel, Croatia and Austria who have already introduced a time limit for the Covid-19 vaccine to be valid for quarantine free travel.
Booster and third doses will not be added to the domestic 'Covid Pass' as it is not a current requirement for individuals to receive booster doses to qualify as fully vaccinated. A booster is not necessary to travel into England.
Prince Charles formally opened a new 1 billion pound AstraZeneca research and development (R&D) facility in Cambridge on Tuesday (November 23), as the company
aims to fuel the growth of its drug pipeline.
AstraZeneca has supplied two billion doses of its Covid-19 vaccine, developed at Oxford University, and is also looking to bring a preventative antibody cocktail
against Covid-19 to market.
Prince Charles, son of Queen Elizabeth and heir to the throne, saw an exhibit on the pandemic and a demonstration of how augmented reality headsets can help with
lab work, before hearing about the company's net-zero targets.
"The last two years have been some of the most difficult of a generation," Prince Charles said in a speech.
While thanking the provisionally registered pharmacists and their employers for supporting NHS services during the pandemic, the General Pharmaceutical Council (GPhC) has asked the 63 eligible candidates to join the main register by January 31 to continue practicing.
A total number of 4,799 provisionally-registered pharmacists have been on the provisional register since it was introduced in July 2020 in response to the Covid-19
pandemic, which had affected the registration assessment schedule.
As of Tuesday (January 18), 237 were still on the provisional register, of which 84 have begun the process to join the main register, 90 did not sat an assessment, while 63 eligible candidates are yet to start their application.
The register enabled trainees who had completed their training to support NHS services and provide patient care effectively as provisionally-registered pharmacists,
while they waited to sit the registration assessment.
After providing three potential opportunities to trainees to sit the registration assessment - in March, July and November 2021, the provisional register will close
on January 31, 2022.
Bas Vorsteveld, who was made vice president and general manager for Great Britain & Ireland (GBI) in November last year, is joined by Monica Michalopoulou as GBI marketing director and Onyeka Anugwom as GBI commercial excellence director GSK Consumer Healthcare.
He took over from Jonathan Workman, who held the position from 2018, and has now moved into the role of Business Unit general manager for Northern Europe.
Vorsteveld, who has 15 years' industry experience, played at major part in the merger of Novartis and GSK consumer healthcare businesses. Most recently, he held
the role of VP & head of commercial excellence EMEA LATAM at GSK Consumer Healthcare, where he spearheaded international sustainability initiatives.
Commenting on his new role, Vorsteveld said: "I am incredibly honoured to have been a part of GSK Consumer Healthcare's journey to date and it is our collective ambition to deliver better everyday health with humanity for our customers, with a laser focus on 'self-care'.
"The recent pandemic has shown us that healthcare matters more now than ever before for our consumers. We want to redefine the role that self-care plays in people's lives, because it can bring long-term benefits for individuals and society, and is a key component of a sustainable healthcare system.
The Department of Health and Social Care (DHSC) has issued a Serious Shortage Protocol (SSP) for Salazopyrin EN-Tabs 500 mg due to ongoing shortage of the medicine.
With SSP014 in place from today (November 26), for every prescription one Sulfasalazine 500mg gastro-resistant (GR) tablet will be supplied.
This SSP will expire on December 20, 2021, and PSNC will update contractors in case of any change.
PSNC has advised pharmacists to notify the patient's prescriber while supplying in accordance with this SSP.
Besides, the supervising pharmacist should refer back to the prescriber if a non-chewable atorvastatin tablet would not be appropriate for the patient.
Hypovase (prazosin) 500 microgram tablets, manufactured by drug major Pfizer, will remain out of stock until mid-January 2022 due to a manufacturing issue.
The Department of Health and Social Care (DHSC) and NHS England and Improvement (NHSE&I) have issued a supply disruption alert for the medicine that is used to treat heart-related troubles.
Pfizer, the sole supplier of prazosin 500mg tablets in the UK, is out of stock from late November 2021, and had discontinued the Hypovase® (prazosin) 1mg tablets in May 2021.
Advice for healthcare professionals
In the given situation, prescribers need to review all affected patients to discuss management plans.
Meanwhile, alternative medicine alpha blockers remain available to support an uplift in demand.
New mask mandates and other measures aimed at curbing the spread of the Omicron coronavirus variant came into England today, as Prime Minister Boris Johnson eyes an expanded booster programme to help increase protection against Covid-19.
From Tuesday morning (November 30), face masks are compulsory on transport and in shops, banks and hair salons.
All international travellers must take a PCR test by the end of the second day after they arrive, and self-isolate until they get their result. That is in addition to restrictions on arrivals from 10 southern African countries, who have to enter hotel quarantine.
Britain has reported 11 cases of the Omicron variant so far, and while the government says this number will rise, it says it is important to slow its spread until more is known about the variant's transmissibility and impact on vaccines.
Existing Covid-19 inoculations will struggle against the fast-spreading Omicron variant, the head of vaccine manufacturer Moderna warned on Tuesday (November 30), as countries ramp up vaccination programmes and impose further restrictions in an effort to curb growing concern.
First reported to the World Health Organization in South Africa less than a week ago, the new strain has rapidly spread from Africa to the Pacific, and from Europe
to North America as dozens of countries have announced travel restrictions.
While no deaths have yet been reported from Omicron, and it could take weeks to know how infectious and how resistant the strain may prove to vaccines, its emergence underscores how besieged the world remains by Covid-19, nearly two years after the first cases were recorded.
Stephane Bancel, the head of US vaccine manufacturer Moderna, told the Financial Times in an interview published today that data would be available on the effectiveness of vaccines in the two weeks' time, but that scientists were pessimistic.
Pharmaceutical Services Negotiating Committee expects the next round of negotiations to set the arrangements for the Community Pharmacy Contractual Framework (CPCF) in 2022/23 - Year 4 of the five-year CPCF deal, to begin soon.
The negotiator held a meeting on November 24 and 25 to discuss the burning issues affecting the sector and to plan for upcoming negotiations with the Department of Health and Social Care (DHSC) and NHS England and NHS Improvement (NHSE&I).
It aims to complete these negotiations by April, allowing ample time for contractors to make arrangement prior to the beginning of the financial year.
PSNC vice-chair, and independent contractor, Bharat Patel said the entire sector is worried about the "outlook for pharmacies as we head into a difficult winter," and is working to find solutions.
He noted that PSNC "will be bringing proposals for additional funding and support, particularly around the treatment of 'walk-in' patients, to the table, along with a heavy dose of realism for government and the NHS about the current challenges in the sector."
While expecting a difficult round of discussion with the government, Patel remained optimistic about a favourable outcome for pharmacies.
Researchers from the University of Oxford today (December 8) started recruiting for a clinical trial to test novel antiviral Covid-19 treatments for early use in the illness by people in the community and those who are at higher risk of complications.
Partnering with the National Institute for Health Research (NIHR), colleagues in several UK universities, and the NHS UK-wide, the Platform Adaptive trial of NOvel antiviRals for eArly treatMent of Covid-19 In the Community (PANORAMIC), is a national priority trial, and will be open to participants from across the UK.
The first treatment to be tested by the UK Antiviral Taskforce will be molnupiravir, a Covid antiviral pill already licensed by the MHRA.
Britain became the first country in the world to approve molnupiravir, which was jointly developed by U.S.-based Merck & Co Inc and Ridgeback Biotherapeutics, in November.